Bayer's Pharma Margin Pledge Is Now the Only Number That Matters
Published on 11/20/2026 at 13:02 | Editorial boerse-global.deTwo brokers, one rating, and a EUR 13.50 spread. That is the unusual position Bayer investors found themselves in this week, after Jefferies and Berenberg both reaffirmed a "Hold" on the German life-sciences group while publishing price targets that point in opposite directions.
Jefferies, fresh from its London pharma conference, kept its target at EUR 48.50 on Thursday. A day earlier, Berenberg's Sebastian Bray had lifted his from EUR 53.50 to EUR 62.00. Measured against Thursday's close, the lower figure implies downside and the higher one leaves room to run — a reminder that a shared recommendation can conceal sharply different views on what the operating business is actually worth.
The stock itself has been drifting. Bayer slipped 2.3% on Thursday in a weak German market, and by the following session was off another 0.2% at EUR 54.36 — a level that still sits above the Jefferies target.
A Margin Upgrade, Not Yet a Margin Proof
What separates the two camps is the pharmaceutical division's profitability. Bayer has raised its guidance for the pharma EBITDA margin to 25% to 27% for 2026, up from a previous 23% to 25%, and has lifted its outlook for group EBITDA before special items and for free cash flow alongside it.
Should investors sell immediately? Or is it worth buying Bayer?
The third quarter of 2026 offered a first snapshot: group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Whether the improved margin expectation shows up in reported figures is the question that will decide which target the market gravitates toward. A brighter forecast is not the same thing as demonstrated profitability.
Asundexian Arrives, but Approval Is Not Revenue
The November US clearance of Sunharbo, whose active ingredient is asundexian, gives Bayer a fresh commercial avenue. The FDA approved the drug for stroke prevention in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, and Bayer said it would begin shipping in the US from mid-to-late November.
A launch, however, says nothing on its own about the size of the earnings contribution. For the margin debate, the relevant test is whether Asundexian translates into profit — not whether it cleared regulators.
Berenberg's Longer Game
Bray's case extends beyond the current quarter. He floated the possibility of an initial public offering of Monsanto toward the end of the decade, with the proceeds potentially channeled into pharmaceutical development. That kind of structural move would give the higher target a strategic underpinning rather than a purely operational one.
Bayer at a turning point? This analysis reveals what investors need to know now.
What the Next Print Must Show
If Bayer delivers on the raised pharma margin and the improvement flows through to group earnings, the scenario behind the EUR 62.00 target gains real substance. Should the margin fall short of the upgraded expectations, investors will also need to ask whether the improved group guidance can survive — and in that case the EUR 48.50 target carries more weight.
The coming results release is the decisive checkpoint. Confirm the higher pharma profitability, and attention shifts to how much of it reaches the group bottom line. Disappoint on the margin, and the optimistic case loses its central piece of evidence.
Ad
Bayer Stock: New Analysis - 20 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
